11.39
+0.115(+1.02%)
Currency In USD
| Previous Close | 11.27 |
| Open | 11.1 |
| Day High | 11.88 |
| Day Low | 11.1 |
| 52-Week High | 16.44 |
| 52-Week Low | 5.79 |
| Volume | 2.08M |
| Average Volume | 3.52M |
| Market Cap | 2.43B |
| PE | -7.96 |
| EPS | -1.43 |
| Moving Average 50 Days | 12.23 |
| Moving Average 200 Days | 10.72 |
| Change | 0.12 |
If you invested $1000 in Ocular Therapeutix, Inc. (OCUL) 10 years ago, it would be worth $1,784.48 as of January 20, 2026 at a share price of $11.385. Whereas If you bought $1000 worth of Ocular Therapeutix, Inc. (OCUL) shares 5 years ago, it would be worth $571.82 as of January 20, 2026 at a share price of $11.385.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Ocular Therapeutix™ Announces Plans to Accelerate NDA Submission Timeline for AXPAXLI™ in Wet AMD
GlobeNewswire Inc.
Dec 08, 2025 12:00 PM GMT
Ocular intends to submit AXPAXLI New Drug Application (NDA) for wet AMD shortly after year one data from SOL-1, if positive SOL-1 topline data remain on track for 1Q 2026 Ocular plans to leverage the 505(b)(2) regulatory pathway for new drug approval
Ocular Therapeutix™ Announces First Patient Randomized in HELIOS-3 Phase 3 Registrational Program for AXPAXLI™ in NPDR
GlobeNewswire Inc.
Nov 24, 2025 12:00 PM GMT
First patient randomized into HELIOS-3, which along with HELIOS-2 form the basis of AXPAXLI’s registrational program in non-proliferative diabetic retinopathy (NPDR) HELIOS-2 and HELIOS-3 are global, complementary superiority trials using a novel ord
Ocular Therapeutix™ to Participate in November and December Investor Conferences
GlobeNewswire Inc.
Nov 12, 2025 12:00 PM GMT
BEDFORD, Mass., Nov. 12, 2025 (GLOBE NEWSWIRE) -- Ocular Therapeutix, Inc. (NASDAQ: OCUL, “Ocular”), an integrated biopharmaceutical company committed to redefining the retina experience, today announced participation in several upcoming investor c